Literature DB >> 26323542

Anticancer drugs: Repressing LXRs to starve cancer.

Katie Kingwell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26323542     DOI： 10.1038/nrd4714

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Authors:  Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris
Journal:  Cancer Cell       Date:  2015-06-25       Impact factor: 31.743
  1 in total
  1 in total

1.  Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Authors:  Guangzhen Wu; Qinglian Wang; Yingkun Xu; Jianyi Li; Hongge Zhang; Guanghui Qi; Qinghua Xia
Journal:  Cell Death Dis       Date:  2019-05-28       Impact factor: 8.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.